We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+48.62%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$958M
AUM Growth
+$204M
Cap. Flow
+$76.9M
Cap. Flow %
8.03%
Top 10 Hldgs %
62.37%
Holding
42
New
13
Increased
9
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$48M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$32.9M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$29.6M
4
PRTA icon
Prothena Corp
PRTA
+$20.3M
5
BLUE
bluebird bio
BLUE
+$13.4M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$94M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$29.1M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$19.4M
4
OMER icon
Omeros
OMER
+$11.3M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 63.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
CALL
Acadia Pharmaceuticals
ACAD
$4.49B
$144M 15.05%
5,250,000
+250,000
+5% +$5.23M
DYAX
2
DELISTED
DYAX CORPORATION
DYAX
$71.5M 7.46%
10,418,379
-490,000
-4% -$2.22M
NVAX icon
3
Novavax
NVAX
$1.21B
$65.5M 6.84%
1,040,000
+181,460
+21% +$10.2M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.49B
$55.9M 5.84%
2,035,510
-4,494,300
-69% -$94M
TXMD icon
5
TherapeuticsMD
TXMD
$23.4M
$48.4M 5.05%
330,573
+105,321
+47% +$12.7M
INSM icon
6
Insmed
INSM
$22.4B
$46.6M 4.86%
2,983,319
+550,000
+23% +$6.99M
SGMO
7
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$44.7M 4.66%
4,258,244
-1,109,850
-21% -$11M
ACHN
8
DELISTED
Achillion Pharmaceuticals
ACHN
$43.7M 4.56%
14,457,061
+7,001,859
+94% +$48M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.43B
$42.5M 4.44%
+5,844,700
New +$29.6M
LUMO
10
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$34.6M 3.61%
204,477
– –
PRTA icon
11
Prothena Corp
PRTA
$448M
$33.3M 3.48%
1,646,399
+1,148,592
+231% +$20.3M
SGMO
12
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$31.5M 3.28%
3,000,000
– –
XOMA
13
DELISTED
Xoma
XOMA
$31.1M 3.24%
345,776
+10,848
+3% +$986K
DSCI
14
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$24.7M 2.58%
1,994,876
– –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$24.2M 2.52%
23,187
+728
+3% +$778K
KERX
16
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$24.1M 2.52%
2,391,261
-3,268,024
-58% -$29.1M
HPTX
17
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$23.6M 2.46%
902,858
– –
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
$16.9M 1.77%
+3,045,380
New +$32.9M
ACHN
19
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$16.6M 1.73%
5,500,000
+3,500,000
+175% +$24M
BLUE
20
DELISTED
bluebird bio
BLUE
$12.6M 1.32%
+36,085
New +$13.4M
RMTI icon
21
PUT
Rockwell Medical
RMTI
$27.6M
$11.4M 1.19%
+9,091
New +$6.17M
MYGN icon
22
Myriad Genetics
MYGN
$485M
$10.6M 1.1%
+450,000
New +$12.8M
OMER icon
23
Omeros
OMER
$835M
$10.3M 1.07%
1,055,311
-1,897,693
-64% -$11.3M
KERX
24
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$10.1M 1.05%
1,000,000
– –
AMPE
25
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$9.94M 1.04%
+4,419
New +$8.55M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, RA Capital Management held 42 positions worth $958M, up 27% from $754M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

RA Capital Management deployed $76.9M of net new capital in Q3 2013, opening 13 new positions and adding to 9 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 3,045,380 shares worth $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 71% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $94M trimmed.

  • RA Capital Management's largest Q3 2013 buy was ChemoCentryx, Inc.: 3,045,380 shares worth $16.9M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q3 2013, an estimated $48M increase.
  • RA Capital Management's biggest Q3 2013 reduction was Acadia Pharmaceuticals, cutting an estimated $94M.
  • RA Capital Management fully exited RECEPTOS INC COM STK (DE) in Q3 2013, selling an estimated $19.4M.
  • RA Capital Management's ten largest holdings make up 62% of its $958M portfolio in Q3 2013.
  • RA Capital Management opened 13 new positions and closed 3 in Q3 2013.
  • RA Capital Management's portfolio value rose 27% quarter-over-quarter to $958M.

Based on RA Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.